Which has better earnings & valuation, REPL or FBRX?

Forte Biosciences is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Replimune Group N/A N/A -$247.30M -$3.44 N/A Forte Biosciences N/A N/A -$69.38M -$4.64 N/A

Is REPL or FBRX more profitable?

Replimune Group's return on equity of -102.69% beat Forte Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Replimune Group N/A -102.69% -72.22% Forte Biosciences N/A -106.17% -85.50%

Is AVTX or FBRX more profitable?

Avalo Therapeutics' return on equity of -97.54% beat Forte Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Avalo Therapeutics N/A -97.54% -72.42% Forte Biosciences N/A -106.17% -85.50%

Forte Biosciences (FBRX) Competitors

$21.03 0.00 (0.00%)

Closing price 06/26/2026 04:00 PM Eastern

Extended Trading

$20.88 -0.15 (-0.71%)

As of 06/26/2026 04:43 PM Eastern

Compare

FBRX vs. CRON, BIOA, DBVT, REPL, and AVTX

Should you buy Forte Biosciences stock or one of its competitors? MarketBeat compares Forte Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Forte Biosciences include Cronos Group (CRON), BioAge Labs (BIOA), DBV Technologies (DBVT), Replimune Group (REPL), and Avalo Therapeutics (AVTX). These companies are all part of the "pharmaceutical products" industry.

How does Forte Biosciences compare to Cronos Group?

Forte Biosciences (NASDAQ:FBRX) and Cronos Group (NASDAQ:CRON) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, risk, media sentiment, valuation, institutional ownership, profitability, analyst recommendations and dividends.

77.6% of Forte Biosciences shares are held by institutional investors. Comparatively, 8.7% of Cronos Group shares are held by institutional investors. 4.4% of Forte Biosciences shares are held by insiders. Comparatively, 7.8% of Cronos Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Forte Biosciences presently has a consensus target price of $67.00, suggesting a potential upside of 218.59%. Cronos Group has a consensus target price of $2.30, suggesting a potential downside of 18.15%. Given Forte Biosciences' stronger consensus rating and higher possible upside, equities analysts clearly believe Forte Biosciences is more favorable than Cronos Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Forte Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Cronos Group	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

In the previous week, Cronos Group had 3 more articles in the media than Forte Biosciences. MarketBeat recorded 4 mentions for Cronos Group and 1 mentions for Forte Biosciences. Forte Biosciences' average media sentiment score of 1.87 beat Cronos Group's score of 0.91 indicating that Forte Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Forte Biosciences	Very Positive
Cronos Group	Positive

Forte Biosciences has a beta of 2.87, indicating that its stock price is 187% more volatile than the broader market. Comparatively, Cronos Group has a beta of 0.89, indicating that its stock price is 11% less volatile than the broader market.

Cronos Group has higher revenue and earnings than Forte Biosciences. Forte Biosciences is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Forte Biosciences	N/A	N/A	-$69.38M	-$4.64	N/A
Cronos Group	$146.59M	7.15	-$9.45M	$0.01	281.00

Forte Biosciences has a net margin of 0.00% compared to Cronos Group's net margin of -1.14%. Cronos Group's return on equity of -1.26% beat Forte Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Forte Biosciences	N/A	-106.17%	-85.50%
Cronos Group	-1.14%	-1.26%	-1.20%

Summary

Cronos Group beats Forte Biosciences on 8 of the 15 factors compared between the two stocks.

How does Forte Biosciences compare to BioAge Labs?

Forte Biosciences (NASDAQ:FBRX) and BioAge Labs (NASDAQ:BIOA) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, institutional ownership, profitability, dividends, analyst recommendations, media sentiment and valuation.

Forte Biosciences has a beta of 2.87, indicating that its share price is 187% more volatile than the broader market. Comparatively, BioAge Labs has a beta of 0.94, indicating that its share price is 6% less volatile than the broader market.

Forte Biosciences has higher earnings, but lower revenue than BioAge Labs. BioAge Labs is trading at a lower price-to-earnings ratio than Forte Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Forte Biosciences	N/A	N/A	-$69.38M	-$4.64	N/A
BioAge Labs	$10.32M	102.38	-$80.61M	-$2.40	N/A

Forte Biosciences has a net margin of 0.00% compared to BioAge Labs' net margin of -871.75%. BioAge Labs' return on equity of -29.40% beat Forte Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Forte Biosciences	N/A	-106.17%	-85.50%
BioAge Labs	-871.75%	-29.40%	-27.26%

Forte Biosciences presently has a consensus target price of $67.00, indicating a potential upside of 218.59%. BioAge Labs has a consensus target price of $43.50, indicating a potential upside of 83.08%. Given Forte Biosciences' higher possible upside, equities research analysts plainly believe Forte Biosciences is more favorable than BioAge Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Forte Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
BioAge Labs	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

77.6% of Forte Biosciences shares are owned by institutional investors. 4.4% of Forte Biosciences shares are owned by insiders. Comparatively, 20.8% of BioAge Labs shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, BioAge Labs had 4 more articles in the media than Forte Biosciences. MarketBeat recorded 5 mentions for BioAge Labs and 1 mentions for Forte Biosciences. Forte Biosciences' average media sentiment score of 1.87 beat BioAge Labs' score of 0.47 indicating that Forte Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Forte Biosciences	Very Positive
BioAge Labs	Neutral

Summary

BioAge Labs beats Forte Biosciences on 8 of the 15 factors compared between the two stocks.

How does Forte Biosciences compare to DBV Technologies?

Forte Biosciences (NASDAQ:FBRX) and DBV Technologies (NASDAQ:DBVT) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, risk, media sentiment and valuation.

Forte Biosciences currently has a consensus price target of $67.00, indicating a potential upside of 218.59%. DBV Technologies has a consensus price target of $48.50, indicating a potential upside of 200.68%. Given Forte Biosciences' higher possible upside, equities research analysts plainly believe Forte Biosciences is more favorable than DBV Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Forte Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
DBV Technologies	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Forte Biosciences has a net margin of 0.00% compared to DBV Technologies' net margin of -2,895.37%. Forte Biosciences' return on equity of -106.17% beat DBV Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Forte Biosciences	N/A	-106.17%	-85.50%
DBV Technologies	-2,895.37%	-129.88%	-88.84%

In the previous week, DBV Technologies had 2 more articles in the media than Forte Biosciences. MarketBeat recorded 3 mentions for DBV Technologies and 1 mentions for Forte Biosciences. Forte Biosciences' average media sentiment score of 1.87 beat DBV Technologies' score of 0.63 indicating that Forte Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Forte Biosciences	Very Positive
DBV Technologies	Positive

Forte Biosciences has a beta of 2.87, suggesting that its stock price is 187% more volatile than the broader market. Comparatively, DBV Technologies has a beta of -0.99, suggesting that its stock price is 199% less volatile than the broader market.

Forte Biosciences has higher earnings, but lower revenue than DBV Technologies. Forte Biosciences is trading at a lower price-to-earnings ratio than DBV Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Forte Biosciences	N/A	N/A	-$69.38M	-$4.64	N/A
DBV Technologies	$5.64M	169.34	-$146.95M	-$4.46	N/A

77.6% of Forte Biosciences shares are owned by institutional investors. Comparatively, 71.7% of DBV Technologies shares are owned by institutional investors. 4.4% of Forte Biosciences shares are owned by company insiders. Comparatively, 1.1% of DBV Technologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Forte Biosciences beats DBV Technologies on 9 of the 16 factors compared between the two stocks.

How does Forte Biosciences compare to Replimune Group?

Replimune Group (NASDAQ:REPL) and Forte Biosciences (NASDAQ:FBRX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, profitability, earnings, institutional ownership, valuation, media sentiment and dividends.

Forte Biosciences is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Replimune Group	N/A	N/A	-$247.30M	-$3.44	N/A
Forte Biosciences	N/A	N/A	-$69.38M	-$4.64	N/A

Replimune Group's return on equity of -102.69% beat Forte Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Replimune Group	N/A	-102.69%	-72.22%
Forte Biosciences	N/A	-106.17%	-85.50%

Replimune Group has a beta of 0.88, meaning that its stock price is 12% less volatile than the broader market. Comparatively, Forte Biosciences has a beta of 2.87, meaning that its stock price is 187% more volatile than the broader market.

In the previous week, Replimune Group had 4 more articles in the media than Forte Biosciences. MarketBeat recorded 5 mentions for Replimune Group and 1 mentions for Forte Biosciences. Forte Biosciences' average media sentiment score of 1.87 beat Replimune Group's score of 1.28 indicating that Forte Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Replimune Group	Positive
Forte Biosciences	Very Positive

Replimune Group currently has a consensus target price of $6.00, suggesting a potential downside of 48.41%. Forte Biosciences has a consensus target price of $67.00, suggesting a potential upside of 218.59%. Given Forte Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Forte Biosciences is more favorable than Replimune Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Replimune Group	3 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80
Forte Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

92.5% of Replimune Group shares are owned by institutional investors. Comparatively, 77.6% of Forte Biosciences shares are owned by institutional investors. 5.2% of Replimune Group shares are owned by company insiders. Comparatively, 4.4% of Forte Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Replimune Group beats Forte Biosciences on 7 of the 13 factors compared between the two stocks.

How does Forte Biosciences compare to Avalo Therapeutics?

Avalo Therapeutics (NASDAQ:AVTX) and Forte Biosciences (NASDAQ:FBRX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, media sentiment, dividends, earnings, institutional ownership and risk.

Avalo Therapeutics' return on equity of -97.54% beat Forte Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avalo Therapeutics	N/A	-97.54%	-72.42%
Forte Biosciences	N/A	-106.17%	-85.50%

Forte Biosciences has lower revenue, but higher earnings than Avalo Therapeutics. Forte Biosciences is trading at a lower price-to-earnings ratio than Avalo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalo Therapeutics	$60K	15,912.94	-$78.26M	-$5.46	N/A
Forte Biosciences	N/A	N/A	-$69.38M	-$4.64	N/A

In the previous week, Avalo Therapeutics had 6 more articles in the media than Forte Biosciences. MarketBeat recorded 7 mentions for Avalo Therapeutics and 1 mentions for Forte Biosciences. Forte Biosciences' average media sentiment score of 1.87 beat Avalo Therapeutics' score of 0.65 indicating that Forte Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Avalo Therapeutics	Positive
Forte Biosciences	Very Positive

Avalo Therapeutics presently has a consensus price target of $46.67, suggesting a potential upside of 156.95%. Forte Biosciences has a consensus price target of $67.00, suggesting a potential upside of 218.59%. Given Forte Biosciences' higher probable upside, analysts plainly believe Forte Biosciences is more favorable than Avalo Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85
Forte Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

87.1% of Avalo Therapeutics shares are owned by institutional investors. Comparatively, 77.6% of Forte Biosciences shares are owned by institutional investors. 4.5% of Avalo Therapeutics shares are owned by insiders. Comparatively, 4.4% of Forte Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Avalo Therapeutics has a beta of 0.83, indicating that its stock price is 17% less volatile than the broader market. Comparatively, Forte Biosciences has a beta of 2.87, indicating that its stock price is 187% more volatile than the broader market.

Summary

Avalo Therapeutics beats Forte Biosciences on 9 of the 14 factors compared between the two stocks.

Get Forte Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FBRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FBRX vs. The Competition

Export

Metric	Forte Biosciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$292.11M	$3.62B	$6.83B	$12.17B
Dividend Yield	N/A	2.21%	2.66%	6.11%
P/E Ratio	-4.53	21.75	25.89	24.17
Price / Sales	N/A	334.18	546.41	101.77
Price / Cash	N/A	62.10	29.09	36.93
Price / Book	4.46	8.31	10.79	6.38
Net Income	-$69.38M	$23.92M	$3.58B	$337.00M
7 Day Performance	15.04%	1.93%	1.97%	-0.20%
1 Month Performance	10.28%	-0.41%	-0.24%	-1.40%
1 Year Performance	71.67%	65.22%	34.40%	27.76%

Forte Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FBRX Forte Biosciences	1.7562 of 5 stars	$21.03 flat	$67.00 +218.6%	+71.7%	$292.11M	N/A	N/A	5	Positive News Gap Down High Trading Volume
CRON Cronos Group	1.397 of 5 stars	$2.70 +1.9%	$2.30 -14.8%	+47.9%	$1.01B	$159.54M	270.27	450
BIOA BioAge Labs	2.5622 of 5 stars	$22.32 +4.0%	$43.50 +94.9%	N/A	$992.19M	$10.32M	N/A	N/A	Gap Down
DBVT DBV Technologies	3.2158 of 5 stars	$16.11 +2.6%	$48.50 +201.1%	+75.6%	$953.84M	N/A	N/A	80
REPL Replimune Group	1.9895 of 5 stars	$11.42 +2.1%	$4.88 -57.3%	+24.7%	$942.98M	N/A	N/A	210	Positive News Analyst Upgrade Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FBRX) was last updated on 6/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Forte Biosciences (FBRX) Competitors

FBRX vs. CRON, BIOA, DBVT, REPL, and AVTX

How does Forte Biosciences compare to Cronos Group?

Summary

How does Forte Biosciences compare to BioAge Labs?

Summary

How does Forte Biosciences compare to DBV Technologies?

Summary

How does Forte Biosciences compare to Replimune Group?

Summary

How does Forte Biosciences compare to Avalo Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FBRX vs. The Competition

Forte Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Forte Biosciences (FBRX) Competitors

FBRX vs. CRON, BIOA, DBVT, REPL, and AVTX

How does Forte Biosciences compare to Cronos Group?

Do institutionals & insiders hold more shares of FBRX or CRON?

Do analysts recommend FBRX or CRON?

Does the media favor FBRX or CRON?

Which has more volatility & risk, FBRX or CRON?

Which has stronger valuation & earnings, FBRX or CRON?

Is FBRX or CRON more profitable?

Summary

How does Forte Biosciences compare to BioAge Labs?

Which has more volatility and risk, FBRX or BIOA?

Which has higher earnings & valuation, FBRX or BIOA?

Is FBRX or BIOA more profitable?

Do analysts recommend FBRX or BIOA?

Do institutionals and insiders believe in FBRX or BIOA?

Does the media refer more to FBRX or BIOA?

Summary

How does Forte Biosciences compare to DBV Technologies?

Do analysts rate FBRX or DBVT?

Is FBRX or DBVT more profitable?

Does the media favor FBRX or DBVT?

Which has more volatility and risk, FBRX or DBVT?

Which has higher valuation and earnings, FBRX or DBVT?

Do institutionals & insiders believe in FBRX or DBVT?

Summary

How does Forte Biosciences compare to Replimune Group?

Which has better earnings & valuation, REPL or FBRX?

Is REPL or FBRX more profitable?

Which has more risk & volatility, REPL or FBRX?

Does the media prefer REPL or FBRX?

Do analysts rate REPL or FBRX?

Do institutionals and insiders hold more shares of REPL or FBRX?

Summary

How does Forte Biosciences compare to Avalo Therapeutics?

Is AVTX or FBRX more profitable?

Which has preferable valuation & earnings, AVTX or FBRX?

Does the media prefer AVTX or FBRX?

Do analysts rate AVTX or FBRX?

Do insiders and institutionals hold more shares of AVTX or FBRX?

Which has more risk and volatility, AVTX or FBRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FBRX vs. The Competition

Forte Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools